Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Debt to Equity (2016 - 2026)

Insight Molecular Diagnostics' Debt to Equity history spans 7 years, with the latest figure at -$0.01 for Q4 2025.

  • On a quarterly basis, Debt to Equity rose 26.77% to -$0.01 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.01, a 26.77% increase, with the full-year FY2025 number at -$0.01, up 26.77% from a year prior.
  • Debt to Equity hit -$0.01 in Q4 2025 for Insight Molecular Diagnostics, up from -$0.11 in the prior quarter.
  • Over the last five years, Debt to Equity for IMDX hit a ceiling of $0.63 in Q2 2025 and a floor of -$0.11 in Q3 2025.
  • Historically, Debt to Equity has averaged $0.05 across 5 years, with a median of $0.01 in 2022.
  • Biggest five-year swings in Debt to Equity: soared 3456.76% in 2023 and later plummeted 281.62% in 2025.
  • Tracing IMDX's Debt to Equity over 5 years: stood at $0.02 in 2021, then tumbled by 85.07% to $0.0 in 2022, then soared by 3456.76% to $0.11 in 2023, then plummeted by 116.43% to -$0.02 in 2024, then rose by 26.77% to -$0.01 in 2025.
  • Business Quant data shows Debt to Equity for IMDX at -$0.01 in Q4 2025, -$0.11 in Q3 2025, and $0.63 in Q2 2025.